Novo Nordisk A/S: FDA Posts Briefing Materials Prior to Advisory Committee Meeting for Insulin Degludec and Insulin Degludec/Insulin Aspart

Published: Nov 06, 2012

BAGSVAERD, DENMARK--(Marketwire - November 06, 2012) - Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the New Drug Applications (NDA) for insulin degludec and insulin degludec/insulin aspart, which will take place on 8 November 2012.

The briefing documents from Novo Nordisk and the FDA, which will form the basis for the Advisory Committee's discussion, provide an overview of the non-clinical and clinical data for insulin degludec and insulin degludec/insulin aspart for the treatment of diabetes.

Company Announcement No 71 2012:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Further information
Mike Rulis
+45 3079 3573
Email Contact

Ambre Morley (US)
+1 609 216 5240
Email Contact

Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact

Frank Daniel Mersebach
+45 4442 0604
Email Contact

Lars Borup Jacobsen
+45 3075 3479
Email Contact

Jannick Lindegaard (US)
+1 609 786 4575
Email Contact

Back to news